Alpha Tau Announces Interim Results From Safety And Feasibility Trial Of Alpha DaRT Treatment Of Advanced Pancreatic Cancer
Alpha Tau Announces Interim Results From Safety And Feasibility Trial Of Alpha DaRT Treatment Of Advanced Pancreatic Cancer
Alpha Tau 公布晚期胰腺癌的 Alpha Dart 治疗安全性和可行性试验的中期结果
- Interim data read-out of the first five treated patients demonstrated successful delivery in all five cases, as well as no product-related Serious Adverse Events -
-对前五名接受治疗的患者的中期数据显示，所有五例病例均成功分娩，没有与产品相关的严重不良事件-
- First five patients received conservative partial tumor coverage, and in patients with higher radium-224 levels, increased tumor responses were observed, with the last three patients presenting two stable disease responses and one partial response at last measurement -
-前五名患者接受了保守的部分肿瘤覆盖率，在镭224水平较高的患者中，观察到肿瘤反应增强，最后三名患者在最后一次测量时表现出两种稳定的疾病反应和一种部分反应-
JERUSALEM, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the "Company") (NASDAQ:DRTS, DRTSW))))), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT, announced today the release of interim results from treatment of...
耶路撒冷，2023 年 11 月 28 日（GLOBE NEWSWIRE）...
登录免费看全文
登录/注册